Seller record · Telehealth service
Gaya Wellness
Fails 3 of 8 criteria. S3, pharmacy identification: No filling pharmacy is named. The program pages refer only to access to a compounding pharmacy network. 2 more criteria also fail; see the table below.
At a glance
Gaya WellnessTelehealth service
- Price
- Weight loss program with compounded GLP-1 included from $349 a month on a quarterly commitment
- Sells
- compounded semaglutide, compounded tirzepatide, retatrutide, and 24 more
- FDA letters
- None on file
Telehealth service. Passes 5 of 8 criteria. Recorded against Standard v1.1.
A concierge virtual practice in Florida led by a board-certified OB/GYN for women over 40, offering compounded semaglutide and tirzepatide, retatrutide, hormone therapy and a long list of peptide therapies. Treatment follows a paid physician consultation, and no pharmacy is named.
Operating entity No legal entity name appears in the header, the footer, on the contact page, the about page or the program pages, and the site publishes no terms or privacy policy.
Dispositions
| Code | Criterion | Disposition | Where it appears |
|---|---|---|---|
| S1 | Prescriber requirement | PASS | Gaya Wellness' website; Gaya Wellness' weight loss concierge page; Gaya Wellness' about page |
| S2 | Prescription gating | PASS | Gaya Wellness' website; Gaya Wellness' weight loss concierge page; Gaya Wellness' membership pricing page |
| S3 | Pharmacy identification | FAIL | Gaya Wellness' website; Gaya Wellness' weight loss concierge page |
| S4 | Compounding disclosure | FAIL | Gaya Wellness' weight loss concierge page; Gaya Wellness' membership pricing page; Gaya Wellness' semaglutide page; Gaya Wellness' retatrutide treatment page |
| S5 | Analytical documentation | FAIL | Gaya Wellness' peptide therapy page; Gaya Wellness' weight loss concierge page |
| S6 | Business address | PASS | Gaya Wellness' website; Gaya Wellness' contact page |
| S7 | Price disclosure | PASS | Gaya Wellness' weight loss concierge page; Gaya Wellness' membership pricing page; Gaya Wellness' website |
| S8 | Enforcement status | PASS | FDA warning-letter index |
Evidence, criterion by criterion
The evidence behind each disposition in the table above, where it appears, and its date.
Products shown on the seller's own pages at the recorded date: compounded semaglutide, compounded tirzepatide, retatrutide, tesamorelin, sermorelin, BPC-157, CJC-1295, ipamorelin, MOTS-c, NAD+, PT-141, GHK-Cu, epitalon, AOD-9604, melanotan II, MK-677, HGH, IGF-1, cerebrolysin, DSIP, LL-37, selank / semax, SLU-PP-332, tesofensine, thymosin alpha-1, thymosin beta-4, bioidentical hormone replacement therapy.
Other sellers of the same products
Who sells semaglutideWho sells tirzepatideWho sells sermorelinWho sells NAD+Who sells PT-141Who sells GHK-CuWho sells tesamorelinWho sells BPC-157Who sells MOTS-cWho sells semaxWho sells epitalonWho sells ipamorelinWho sells retatrutide
Dispositions recorded against Standard v1.1. Method and null semantics: how checks are performed. This record is not a review and contains no medical advice.